SCHEMBL2962785

SCHEMBL2962785

CCCc1ccc2c(Nc3cc(COc4ccccc4)ccc3Sc3ccc(O)cc3)ccnc2n1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 1/20 0.45
AKT2 P31751 1/20 0.45
BCHE P06276 3/20 0.32
SREBF2 Q12772 1/20 0.32
PRMT5 O14744 1/20 0.32
EGFR P00533 1/20 0.31
ERBB2 P04626 1/20 0.31
SIRT2 Q8IXJ6 1/20 0.31
LNPEP Q9UIQ6 1/20 0.31
LMNA P02545 3/20 0.31
CYP1A2 P05177 1/20 0.31
PTGS1 P23219 1/20 0.31
SLC6A2 P23975 1/20 0.31
CYP2C19 P33261 1/20 0.31
PTGS2 P35354 1/20 0.31
SLC6A3 Q01959 1/20 0.31
HIF1A Q16665 1/20 0.31
HDAC6 Q9UBN7 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
RIPK2 O43353 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2962127 0.92 PIM1 (0.50) PIM1AKT2BCHEEGFRERBB2
SCHEMBL2971513 0.89 PIM1 (0.54) PIM1AKT2PRMT5SIRT2LMNA
SCHEMBL2964171 0.87 PIM1 (0.45) PIM1AKT2SREBF2LMNASMN1; SMN2
SCHEMBL2965288 0.87 PIM1 (0.49) PIM1AKT2SREBF2LMNA
SCHEMBL2960452 0.86 PIM1 (0.45) PIM1AKT2
SCHEMBL2961388 0.86 PIM1 (0.49) PIM1AKT2
SCHEMBL2970350 0.86 PIM1 (0.45) PIM1AKT2
SCHEMBL2970398 0.84 SREBF2 (0.42) PIM1AKT2SREBF2EGFR
SCHEMBL2961869 0.84 PIM1 (0.42) PIM1AKT2SREBF2LMNASMN1; SMN2
SCHEMBL2969836 0.80 PIM1 (0.55) PIM1AKT2LMNASMN1; SMN2RIPK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8338605-B2 Anti-viral compounds ABBOTT LABORATORIES (US) 2012-12-25 US disclosed
US-20100256139-A1 Anti-Viral Compounds ABBOTT LABORATORIES (US) 2010-10-07 US disclosed
EP-1979349-B1 ANTI-VIRAL COMPOUNDS ABBOTT LAB (US) 2010-07-28 EP disclosed
US-7763731-B2 Anti-viral compounds ABBOTT LABORATORIES (US) 2010-07-27 US disclosed
EP-1979349-A2 ANTI-VIRAL COMPOUNDS Abbott Laboratories (US) 2008-10-15 EP disclosed
US-20070232645-A1 ANTI-VIRAL COMPOUNDS ABBVIE INC. 2007-10-04 US disclosed
WO-2007076035-A2 ANTI-VIRAL COMPOUNDS ABBOTT LABORATORIES (US) 2007-07-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070232645-A1 ANTI-VIRAL COMPOUNDS HAVCR2, MAVS, EIF2AK2 PIM1 2963/4885AKT2 3903/4885BCHE 2656/4885
US-20100256139-A1 Anti-Viral Compounds HAVCR2, MAVS, EIF2AK2 PIM1 2963/4885AKT2 3903/4885BCHE 2656/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.